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Abstract 
Whatever the outcome, pregnancy provides the opportunity to offer effective contraception to couples motivated to avoid 
another pregnancy. This narrative review summarizes the evidence for health providers, drawing attention to current 
guidelines on which contraceptive methods can be used, and when they should be started after pregnancy, whatever its 
outcome. Fertility returns within 1 month of the end of pregnancy unless breastfeeding occurs. Breastfeeding, which itself 
suppresses fertility after childbirth, influences both when contraception should start and what methods can be used. 
Without breastfeeding, effective contraception should be started as soon as possible if another pregnancy is to be avoided. 
Interpregnancy intervals of at least 6 months after miscarriage and 1‐2 years after childbirth have long been recommended 
by the World Health Organization in order to reduce the chance of adverse pregnancy outcome. Recent research suggests 
that this may not be necessary, at least for healthy women <35 years old. Most contraceptive methods can be used after 
pregnancy regardless of the outcome. Because of an increased risk of venous thromboembolism associated with estrogen‐
containing contraceptives, initiation of these methods should be delayed until 6 weeks after childbirth. More research is 
required to settle the questions over the use of combined hormonal contraception during breastfeeding, the use of 
injectable progestin‐only contraceptives before 6 weeks after childbirth, and the use of both hormonal and intrauterine 
contraception after gestational trophoblastic disease. The potential impact on the risk of ectopic pregnancy of certain 
contraceptive methods often confuses healthcare providers. The challenges involved in providing effective, seamless 
service provision of contraception after pregnancy are numerous, even in industrialized countries. Nevertheless, the clear 
benefits demonstrate that it is worth the effort.  
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1 | INTRODUCTION 
Contraception saves lives and pregnancy provides an opportunity to offer effective contraception to couples motivated to 
avoid another pregnancy who, in some countries, may have very limited contact with healthcare providers. Not all 
pregnancies are intended: in 2012, an estimated 40% of all pregnancies worldwide were unintended. In Scotland in 2004‐
05, 90% of pregnancies among women requesting abortion were clearly unintended; 26% of women attending an antenatal 
clinic were ambivalent about pregnancy intention, and 9% had definitely not intended pregnancy when they conceived. An 
estimated 12% of miscarriages and ectopic pregnancies in the UK are unintended at conception. All women should be 
offered effective contraception after pregnancy, whatever the outcome. Yet the opportunity is often missed. Data from 57 
low‐ and middle‐income countries demonstrated that 62% of women giving birth in the preceding year did not initiate 
contraception immediately postpartum. Even in high‐income countries, provision of effective contraception after delivery is 
often sub‐optimal. Only around 50% of postpartum women in a Texan study expressing a preference for either long‐acting 
reversible contraception (LARC) or sterilization received their preferred method. About 70% of pregnancies occurring within 
1 year postpartum in the USA are unintended. In Scotland, over 13% of parous women presenting for induced abortion had 
been pregnant within the preceding year. Repeat induced abortion is common worldwide even in countries with excellent 
contraceptive services. In the Netherlands for example, approximately 36% of all abortions are repeats. 
Health services everywhere are often fragmented; healthcare providers often work in silos; and healthcare providers 
managing pregnancy simply do not think about giving contraceptive advice, believing that someone else will take care of it. 
The UK NICE guideline on the management of miscarriage and ectopic pregnancy (EP), for example, does not mention 
asking about the intendedness of the pregnancy or the need for contraception. This paper reviews the evidence, and 
recommendations, for contraception after pregnancy ending in either childbirth, induced or spontaneous abortion, or 
ectopic or molar pregnancy. It highlights areas of controversy and, where indicated, makes suggestions for further research. 
  
2 | MATERIAL AND METHODS 
A small group of experts, chosen for their knowledge of the evidence and their familiarity with clinical practice in Europe, 
met to discuss the topic of contraception after childbirth. Eight of them prepared oral presentations summarizing the 
available evidence on which contraceptives could be used, and when they should be started, after pregnancy ending in 
childbirth, induced or spontaneous abortion, EP and gestational trophoblastic disease (GTD); and the barriers to their 
effective provision by healthcare services. Individual presenters selected the most recent systematic reviews available, 
undertaking searches performed in Medline, Popline, EMBASE, and Cochrane library databases for relevant English 
language publications from 1970 to mid‐2018. If topics were not covered by systematic reviews, the same databases were 
used to search for the most recent primary research papers. Each presenter provided a written, referenced summary of 
their presentation, which was circulated some 4 weeks before the meeting of the Annual Capri Workshop in Reproductive 
Medicine (held in October 2018). Although not formally assessed for quality, the evidence presented was critically reviewed 
and discussed in detail by the workshop participants. Before the end of the meeting, the participants agreed an outline of 
the resulting narrative review presented here. 
 
Key message 
Postpartum contraception saves lives. Most women can use most methods of contraception after pregnancy. Because 
services work in silos, seamless provision of contraception after pregnancy, especially immediate postpartum provision of 
long‐acting methods is challenging—even in industrialized countries. Nevertheless, the clear benefits demonstrate that it is 
worth the effort. 
 
2.1 | Contraception after childbirth 
After childbirth, Cleland et al suggest that on a global scale contraception prevents some 30% of maternal deaths and 10% 
of infant deaths if pregnancies are spaced >2 years apart. Based on the observation that pregnancies within the first year 
postpartum have increased risks for fetal and early neonatal death, preterm birth, low birthweight, and small‐for‐
gestational‐age infants, in 2007 the World Health Organization (WHO) recommended waiting at least 2 years after 
childbirth before attempting the next pregnancy. In a report published in 2013, WHO further advised that if women wait 2 
years to conceive again, under‐5 mortality decreases by 13%, and by 25% following 3 years delay. However, a recent study 
using methodology adjusting for a woman's predisposition to have these adverse pregnancy outcomes questioned the 
causal link between interpregnancy intervals and adverse pregnancy outcomes. In a study of women giving birth in Sweden, 
 short interpregnancy intervals (0‐3 months) were not causally associated with increased risk of stillbirth or early neonatal 
death. A study from British Columbia confirmed the lack of association for women under 35 years but cautioned against 
short interpregnancy intervals for older women. In low‐ and middle‐income countries where maternal and perinatal 
mortality and morbidity are high and where women may often start, and end, a pregnancy undernourished and anemic, 
long interpregnancy intervals may be beneficial. In countries where women are commonly delaying first childbirth until well 
into their 30s, where most are healthy, and antenatal care routine and paid parental leave are the norm, short 
interpregnancy intervals may well not be harmful should coupleschoose to start another pregnancy soon after childbirth. 
 
2.2 | When should contraception start after childbirth? 
During pregnancy, high circulating levels of estrogens and progesterone from the placenta suppress gonadotropin levels to 
1% of nonpregnant values. Estrogen stimulates pituitary lactotrophs resulting in high concentrations of prolactin. Without 
lactation after delivery, concentrations of prolactin decline whereas those of luteinizing hormone and follicle‐stimulating 
hormone increase over 30 days, leading to the restoration of menstrual cycles. In nonlactating women, the first menses 
after childbirth is often preceded by anovulation, but by the third menses, over 80% of women have normal ovulatory 
cycles. In a systematic review of the limited data, Jackson and Glasier reported a mean time of first ovulation among 
nonlactating women between 45 and 94 days postpartum. In 20%‐71% of women, first menses was preceded by ovulation 
and up to 60% of these ovulatory cycles were thought to be potentially fertile. Hence, women who do not breastfeed 
should be advised that without contraception pregnancy can occur within the first 2 months after childbirth. If a woman 
breastfeeds, prolactin concentrations remain elevated and gonadotropins are suppressed. The duration of suppressed 
ovarian activity depends on the breastfeeding pattern. Frequent suckling episodes, including at night, prolong ovarian 
suppression. The introduction of artificial milk and/or solid food coincides with a reduction in the frequency and duration of 
breastfeeding episodes and as the suppressive effect of suckling wanes so ovarian activity resumes. In a study of 27 
breastfeeding mothers, first menses occurred at a mean of 32.5 weeks after childbirth, preceded by ovulation in 33%. 
Breastfeeding influences not only when contraception should be started, but also which methods can be used. The 
formalized Lactational Amenorrhea Method advises that another method of contraception should be started when the 
baby reaches 6 months, or sooner if menses returns or exclusive/almost exclusive breastfeeding stops (and supplements 
are introduced). Two controlled studies of Lactational Amenorrhea Method users at 6 months postpartum reported life‐
table pregnancy rates of 0.45% and 2.4%, while 6 uncontrolled studies reported pregnancy rates from 0% to 7.5%. 
 
2.3 | Which methods can be used after childbirth? 
2.3.1 | Hormonal contraception 
The relative risk of venous thromboembolism is increased approximately 5‐fold in pregnancy, and 60‐fold in the 
puerperium, particularly during the first 3 weeks. The risk is theoretically increased by using combined hormonal 
contraception (CHC). Women are advised to wait at least 3 (and preferably 6) weeks before starting CHC. Women with 
additional risk factors for venous thromboembolism must wait 6 weeks. Low‐dose progestogen‐only methods are not 
associated with any increased risk of venous thromboembolism and, although limited evidence suggests a possible small 
increased risk of thrombosis in association with use of DepoProvera, all methods are considered safe (Medical Eligibility 
Criteria for Contraceptive Use [MEC] category 1) for postpartum women. WHO has concerns about the theoretical risk of 
CHC on breastfeeding continuation or exclusivity, and about old reports of possible effects on infant growth or health. It 
advises that CHC should not be used before 6 months postpartum by breastfeeding women, unless no other method is 
available or acceptable (WHO MEC, Category 3). However, most trials published after 2005 do not report any significant 
impact of CHC on breastfeeding duration, breast milk composition, or infant growth, and the UK and US guidance 
recommend that the benefits outweigh the theoretical risks of CHC use after 6 weeks postpartum (Category 2) among 
breastfeeding women. Despite progestogen‐only contraception (POC) having no apparent direct impact on breastfeeding, 
child health or development, WHO still expresses theoretical concern about the potential exposure of the neonate to depo‐
medroxyprogesterone acetate (DMPA) and norethisterone enanthate and recommends delaying initiation of these 
injectable POC methods until after 6 weeks postpartum. The USA and UK do not recommend any such delay. Progestin‐only 
pills and implants can be started immediately after childbirth regardless of infant feeding. 
 
 
 
2.3.2 | Intrauterine contraception 
 Copper intrauterine devices and the levonorgestrel‐releasing intrauterine system (LNG‐IUS) can be inserted during cesarean 
section or within 48 h of vaginal delivery. WHO does not recommend insertion between 48 hours and 4 weeks after 
childbirth because of higher rates of expulsion compared with later interval insertion; however, the US MEC considers that 
the benefit of insertion at this time outweighs the risks. A recent systematic review and meta‐analysis review reported 
expulsion rates of 1.9% for interval insertion, 10.0% for immediate post‐placental insertion and almost 30% for insertion 
between 10 minutes and 4 weeks. Rates of expulsion were higher for the LNGIUS than for copper devices inserted before 4 
weeks (adjusted relative risk 1.91, 95% CI 1.50‐2.43) and after vaginal delivery were 5 times higher than after insertion at 
the time of cesarean section. The risk of uterine perforation is increased throughout lactation and is highest up to 6 months 
after delivery for both copper intrauterine devices and LNG‐IUS (6‐fold increase, 7 per 1000 insertions, underlining the 
importance of postpartum placement of intrauterine contraception (IUC) being performed by experienced healthcare 
providers. IUC insertion should be avoided in women with postpartum sepsis. 
 
2.3.3 | Other methods 
Condoms can be used as soon as needed. Diaphragm or cap fitting should wait until 6 weeks postpartum, when involution 
of the cervix is complete. Fertility awareness‐based methods can be used when the menstrual cycle has resumed. Oral 
emergency contraception, if required, should be offered from 21 days postpartum, but ulipristal acetate is not 
recommended in breastfeeding women. Regret and dissatisfaction may be more common following sterilization performed 
immediately postpartum and this should be done only after careful counseling. 
 
2.4 | Contraception after miscarriage (spontaneous abortion) 
Miscarriage is the commonest adverse pregnancy outcome with estimated rates of 8%‐20%. In the UK, 10% to 15% of all 
pregnancies end in miscarriage and an estimated 12% of these result from unintended pregnancies. 
 
2.5 | When should contraception start after miscarriage? 
First menses occurs at a mean of 29 days after miscarriage, with ovulation preceding menses in all women. Hence, if 
pregnancy is not desired, contraception should be started immediately. WHO recommends waiting at least 6 months 
before trying to conceive again. However, a recent study, using Scottish national data, showed that women with an 
interpregnancy interval of <6 months were less likely to have another miscarriage (adjusted odds ratio 0.66, 95% CI 0.57‐
0.77), preterm delivery (0.89, 0.81‐0.98), or infant of low birthweight (0.84, 0.71‐0.89). A systematic review of 16 studies 
reached similar conclusions. Current evidence suggests that, if pregnancy is desired, it is not necessary to use contraception 
after miscarriage, and couples wishing to conceive again should be advised to try as soon as they feel ready. 
 
2.6 | What contraceptive methods can be used after miscarriage? 
All methods of contraception can be used without any restriction after miscarriage, and the most effective method 
acceptable should be offered. The risk of expulsion of intrauterine methods may be higher when inserted after a second‐
trimester abortion (versus first trimester).18 Diaphragms and caps should not be fitted before 6 weeks after second‐
trimester miscarriage to allow for complete involution of the cervix. 
 
2.7 | Contraception after induced abortion 
About 90% of women ovulate in the first month after first‐trimester abortion and >50% resume sex within 2 weeks. 
Contraception should therefore be started immediately regardless of gestation, unless sepsis is present, and all methods 
can be used. Repeat abortion is common. LARC methods have been repeatedly shown to reduce the risk of repeat 
unintended pregnancy after induced abortion. IUC can be inserted at surgical abortion or following expulsion of the fetus at 
medical abortion and early insertion increases uptake after both medical and surgical abortion. Increasing use of medical 
abortion and home administration of misoprostol as well as self-assessment of the outcome of the abortion complicate 
contraceptive provision, especially LARC. Fewer US women having medical abortion had an intrauterine device insertion 
compared with those undergoing surgical abortion. Initiation of LARC is being explored at ever earlier intervals. There are 
theoretical concerns about a possible interaction between progestins and the anti‐progesterone mifepristone used for 
medical abortion. Although insertion of a POC implant at the time of mifepristone administration does not impair the 
efficacy of early medical abortion, administration of DMPA with mifepristone increased the risk of failed medical abortion 
 (ongoing pregnancy) compared with DMPA administration delayed until after the abortion (3.5% vs 0.9%). A recent study 
suggested that giving DMPA at the time of misoprostol administration had no effect on ongoing pregnancy rates. A recent 
randomized controlled trial demonstrated an increased risk of partial expulsion with fast‐track (≤3 days) insertion of the 
LNG‐IUS compared with insertion 2‐4 weeks after misoprostol administration (expulsion rates 12‐28 vs. 2%‐4%). However, 
use of LNG‐IUS was higher and pregnancy rates were lower at 1 year if the device had been inserted immediately. As with 
IUC insertion immediately after childbirth, from a public health perspective the advantages of immediate IUC insertion after 
medical abortion (improved uptake and reduced repeat pregnancy rates) appear to outweigh the disadvantage of increased 
expulsion rates. The IUC can be replaced provided expulsion is recognized. Besides the contraceptive methods being 
offered, how the service is being delivered is of importance. Provision of LARC by the same unit providing the abortion care 
decreased the risk of subsequent abortion. 
 
2.8 | Contraception after ectopic pregnancy 
Ectopic implantation of the embryo occurs in 1%‐2% of confirmed pregnancies and accounts for at least 6% of pregnancy‐
related deaths worldwide. With earlier diagnosis and improved treatment, modern management emphasizes preserving 
fertility. There is no evidence of a delay in return to fertility after EP. Women who want to avoid another pregnancy should 
start effective contraception immediately. For women wishing to conceive, the chance of the next pregnancy being 
intrauterine is 60%‐70% regardless of the mode of treatment, but the recurrence rate of EP is 10%‐15% after one EP and 0% 
after a second. All methods of contraception reduce the risk of pregnancy, and women who have had EP may use any 
method. No contraceptive methods increase the risk of EP but some, depending on the mode of action, may do a better job 
of preventing it, a fact that confuses many providers. The absolute risk of EP during contraceptive use is very low. A recent 
systematic review of implants and injectable POC concluded that these methods are highly effective at preventing any 
pregnancy, but that levonorgestrel‐releasing implants (which inhibit ovulation inconsistently) have a higher rate of EP when 
they fail compared with etonogestrel‐releasing implants or DMPA, both of which inhibit ovulation consistently. Low‐dose 
oral POCs, which inhibit ovulation inconsistently and alter tubal motility, significantly reduce the risk of EP compared with 
condoms or no method. Failure of emergency contraception is not associated with an increased risk of EP. Although 
intrauterine contraceptives are the most effective reversible contraceptives, when pregnancy occurs with an intrauterine 
device or LNG‐IUS in situ there is an increased risk of EP and assessment by ultrasound scan should be expedited. The 
cumulative probability of EP 10 years after female sterilization has been reported as 2.4 per 1000 procedures. If EP is 
managed with methotrexate, contraception should be used to avoid a theoretical risk of teratogenesis. Manufacturers 
recommend contraception for 6 months after methotrexate treatment stops, the UK Royal College of Obstetricians and 
Gynaecologists recommends 3 months. Limited evidence suggests that conception within 3 months of methotrexate use is 
not associated with an increased risk of fetal malformation, but pregnancies occurring before 6 months should nevertheless 
be carefully screened. 
 
2.9 | Contraception after gestational trophoblastic disease (molar pregnancy) 
The risk of malignant disease following surgical evacuation of a complete mole is 15%‐20% and after incomplete or partial 
mole it is 0.5%‐5%. Serum human chorionic gonadotropin monitoring is pivotal to managing GTD, allowing early 
identification of malignancy and reliable follow up after chemotherapy. Conception during the monitoring phase raises 
human chorionic gonadotropin and considerably complicates the management, causing delayed diagnoses or misdiagnoses 
of malignancy. Women becoming pregnant within 6 months after diagnosis of molar pregnancy (or 12 months after 
chemotherapy for malignant disease) have an increased risk of morbidity and mortality. For this reason, contraception is 
mandatory and should be started immediately because ovulation returns rapidly after uterine evacuation. Up to 12%‐23% 
of women conceive before the scheduled end of the monitoring period, suggesting that the contraceptive method used 
should be highly effective. Initial studies of hormonal contraception in women with a recent diagnosis of GTD suggested an 
increased risk of developing malignancy. Trophoblastic cells have sex steroid receptors, the proliferative activity of which 
can be modulated by reproductive hormones. Recent epidemiological evidence is reassuring. A systematic review 
concluded a lack of causality between hormonal contraception and GTD and 2 large case series not included in the review 
failed to demonstrate any detrimental effect of hormonal contraception. To date, there is no evidence to contraindicate 
hormonal contraception during the clinical management of women with GTD. All hormonal contraceptives can be used 
without any restrictions after GTD, but, despite no evidence of any detrimental effect on disease outcome, intrauterine 
contraception is contraindicated until after human chorionic gonadotropin levels have returned to normal. Among clinicians 
 there appears to be a natural reluctance to insert a device into a uterus which may be more vulnerable to perforation and, 
perhaps, hemorrhage. 
 
2.10 | Lessons for improving provision of contraception after pregnancy 
The benefits of providing effective contraception after pregnancy are clear. Fertility resumes rapidly after pregnancy 
regardless of outcome. If contraception is left until a follow‐up appointment (which many women fail to attend) many 
women are already at potential risk of pregnancy and those choosing LARC methods often face further delays accessing 
trained providers. Educational interventions about contraceptive use after childbirth, including giving women advice 
antenatally, are generally of low quality. Limited evidence suggests that some educational interventions can increase 
uptake of contraception—including the most effective methods—after childbirth. In Scotland, information given by 
midwives at an antenatal visit has been part of the pathway of a successful initiative to increase LARC uptake after delivery. 
Peri‐abortion information‐giving alone does not appear to influence uptake of LARC or risk of further unplanned pregnancy; 
it should be part of a pathway to facilitate access to and initiation of contraception. Visual and verbal information are 
acceptable to women after both childbirth and abortion. The use of pre‐prepared scripts saves time and ensures consistent 
information; DVDs and webbased information are becoming increasingly acceptable. Most women given information about 
the contraceptive implant using a DVD had knowledge recall as good as with a face‐to‐face consultation and found the DVD 
helpful and easy to understand. Women find contraceptive counseling acceptable during the abortion consultation. 
Telephone counseling about contraception, separated from the abortion consultation, is an alternative model. The “best” 
contraceptive method after pregnancy is the one that the informed individual woman considers most appropriate for her—
and which she is therefore most likely to continue. Information should be provided about all suitable contraceptives and 
should include discussion about the comparative efficacy of all available methods. The least effective methods include male 
and female condoms (failure rate 18%‐20% in the first year of use), spermicides (failure rate 28%) and fertility‐awareness‐
based methods (failure rate 24%). Diaphragms have a moderate failure rate (12%/year) whereas hormonal methods that 
rely on correct and consistent use have failure rates of between 5% and 8% per year. LARC clearly provides the best 
protection against pregnancy with failure rate <1% per year and satisfaction with the most effective LARC methods can be 
high even for women whose initial preference is for a short‐acting method. 
 
2.11 | Barriers to provision 
Many barriers limit provision of contraception after pregnancy, some are more easily overcome than others. Lack of 
knowledge, appropriate training and the ability to prescribe among the cadre of staff who manage the outcome of the 
pregnancy whether childbirth, miscarriage or induced abortion, often deter them from taking responsibility for 
contraceptive provision. Lack of staff trained in insertion childbirth and after abortion. Because services work in silos, 
seamless provision of contraception after pregnancy, especially immediate postpartum provision of long‐acting methods, is 
challenging—even in industrialized countries. For example, negotiating agreement over who should follow‐up women after 
postpartum or post‐abortion IUC insertion has proven surprisingly challenging in the UK. It is worth being imaginative and 
flexible if it facilitates provision of an effective method that ensures prevention of unwanted pregnancy, particularly in 
vulnerable groups like adolescents, single mothers or drug‐users. Postnatal insertion of POC implants in women's homes 
was evaluated in a cohort of 40 Scottish women; the service, provided by specially trained “contraceptive champion” 
community midwives was highly acceptable to the women. 
 
3 | CONCLUSION 
The provision of contraception after pregnancy is not complicated but in the process of managing the pregnancy itself, it is 
something that is often forgotten completely or is rather poorly managed. Clear, evidence‐based advice on which methods 
can be used and when they should be started is readily available on‐line from the WHO, UK and US MEC. The benefits of 
doing a good job are clear. Ensuring the availability of all contraceptive methods, facilitating uptake and ensuring correct 
and consistent use and method continuation are always challenging, but women/couples with a recent pregnancy are often 
highly motivated. Evidence is beginning to emerge on how best to organize services to allow provision of the most effective 
method acceptable to couples/women after pregnancy (whatever the outcome) and to do so at a time that is both 
convenient for the user and ensures high rates of method continuation and satisfaction. It takes flexibility and collaborative 
thinking on the part of service providers, but it is an investment that is well worth making. 
  
 
